Insulet bond offering 'financially sound,' says Leerink Leerink says Insulet's $175M convertible bond offering due in 2019 is "financially sound" as it avoids potentially meaningful share dilution based on the principal of the existing convert. The firm reiterates an Outperform rating on the stock with a $45 price target.
Insulet Q2 postponement may indicate an acquisition is near, says Feltl As previously reported, Feltl upgraded Insulet to Hold from Sell. Analyst Ben Haynor believes the surprising preliminary Q2 release and postponement of full results is odd behavior and may indicate an "acquisition may be afoot." Haynor increased his price target on Insulet to $35 based upon the multiple St. Jude (STJ) is paying to acquire Thoratec (THOR).